Lung Cancer
News
FDA moves to ban menthol in cigarettes
From the Journals
Survival benefit with nivolumab extends to 5 years in NSCLC
Early response portends durable outcome, but the optimal duration of treatment is uncertain.
Conference Coverage
Tislelizumab bests docetaxel in NSCLC
Tislelizumab was associated with better outcomes in patients with locally advanced or metastatic non–small cell lung cancer.
Article
Leveraging the microbiome to enhance cancer treatment
Dr. Alan Lyss reviews research suggesting that an antibiotic can improve the efficacy of radiotherapy.
Conference Coverage
New data dim hopes for ‘triumph of drug discovery’
Latest News
Rankings of most common cancers to shift over next 20 years
“It’s time to shift focus to some of the less commonly diagnosed cancers with the lowest survival rates, like pancreatic and liver cancer.”
Conference Coverage
Presurgical nivo/chemo boosts pCR rates in NSCLC
Article
Steroid-refractory pneumonitis from ICIs: Experience at major centers
From the Journals
Increased cancer risk from night shift due to gene dysregulation?
A simulated night shift schedule significantly altered the normal circadian rhythmicity of genes.
Feature
Cancer screening stopped by pandemic: Repercussions to come?